Abstract
von Willebrand disease (VWD) is the commonest inherited bleeding disorder. The aim of therapy for VWD is to correct the two defects of haemostasis in this disorder, impaired primary haemostasis because of defective platelet adhesion and aggregation and impaired coagulation as a result of low levels of factor VIII. The objective of this guideline is to inform individuals making choices about the treatment and management of VWD including the use of therapeutic products. This is the second edition of this UK Haemophilia Centre Doctors' Organization (UKHCDO) guideline and supersedes the previous edition which was published in 1994. © 2004 Blackwell Publishing Ltd.
Author supplied keywords
Cite
CITATION STYLE
Pasi, K. J., Collins, P. W., Keeling, D. M., Brown, S. A., Cumming, A. M., Dolan, G. C., … Peake, I. R. (2004). Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctor’s Organization. Haemophilia, 10(3), 218–231. https://doi.org/10.1111/j.1365-2516.2004.00886.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.